EDITOR: | June 29th, 2021

Awakn Life Sciences’ Anthony Tennyson on using researched backed psychedelic drugs and therapies to treat Alcohol Use Disorder

| June 29, 2021 | No Comments
image_pdfimage_print

In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of Awakn Life Sciences Corp. (NEO: AWKN) about Awakn’s commitment to use researched backed psychedelic drugs and therapies to treat addictions such as Alcohol Use Disorder.

In this InvestorIntel interview, which may also be viewed on YouTube (click here to subscribe to the InvestorIntel Channel), Anthony went on to say that Alcohol Use Disorder affects 5% of the global population with a 70% relapse rate within the 1st 12 months and accounts for 30% of the global addiction treatment market. Anthony further said that as clinics start to rollout this year starting with the UK, “Awakn will be the only company in the world providing evidence backed ketamine-assisted psychotherapy for Alcohol Use Disorder.”

To watch the full interview, click here

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

To learn more about Awakn Life Sciences Corp., click here

Disclaimer: Awakn Life Sciences Corp. is an advertorial member of InvestorIntel Corp.

This interview, which was produced by InvestorIntel Corp. (IIC) does not contain, nor does it purport to contain, a summary of all the material information concerning the Company” being interviewed. IIC offers no representations or warranties that any of the information contained in this interview is accurate or complete. 

This presentation may contain “forward-looking statements” within the meaning of applicable Canadian securities legislation.  Forward-looking statements are based on the opinions and assumptions of management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken,  as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company’s financial condition or results of operations may negatively impact the value of its securities. Prospective investors are urged to review the Company’s profile on Sedar.com and to carry out independent investigations in order to determine their interest in investing in the Company.

If you have any questions surrounding the content of this interview, please email info@investorintel.com.


Editor:

InvestorIntel.com is a leading online source of investor information that provides public market coverage for both investors and industry alike. A qualified online influencer through ... <Read more about InvestorIntel>


Copyright © 2021 InvestorIntel Corp. All rights reserved. More & Disclaimer »

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.